A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of
investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36
patients from the US will be enrolled in this study.